secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2022-06-07T23:59:59+00:00
Accession:  0001193125-22-168821
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO appoints Jennifer Zachary to board; annual meeting results ratified
-----------------------------------------------------------------------------

- Jennifer Zachary elected Class I director and Audit Committee member, effective June 3, 2022.
- Ms. Zachary receives initial equity award of $550,000 (75% option, 25% RSUs) at $22.84 exercise price.
- Annual meeting re-elected Allan Fox and Alexandra Glucksmann as Class I directors; PwC ratified as auditor.
- Advisory vote on named executive officer compensation approved with 96% of votes cast in favor.
- Ms. Zachary is EVP & General Counsel of Merck, bringing 20+ years of pharma and regulatory experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000119312522168821/0001193125-22-168821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000119312522168821/d345163d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-168821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer